Department of Biomedical Engineering Scholar College of Engineering
Peking University, China
Development of new imaging technology that is capable of non-invasive or minimal invasive, in-vivo, in situ, real-time observation of pharmacological interactions between new drug compounds and diseased cells at the molecular level on the animal model plays a critical role in the translational research activities in new drug discovery.
For the past decade or so, many molecular imaging modalities have been separately developed for such a purpose. These imaging modality includes: optical spectroscopy imaging with single or multi-photon stimulation modalities, optical confocal imaging with single or multi-photon stimulation and optical or spectroscopic reflectance analysis, optical coherence tomography (OCT), photo-acoustic microscopy (PAM) or tomography (PAT), combined with animal sized X-ray CT, animal-sized positron emission tomography (PET), or single positron emission tomography (SPET).
Recently, our group has been devoted a great deal of research efforts in the development of multi-modality molecular imaging technologies that combines many of CT, PET, SPECT, and Fluorescence Molecular Tomography (FMT) into one imaging platform. These integrated four modality imaging technology allows researchers to effectively obtain many critical biochemical information in vivo from the same site by a single or multiple scan through out different disease-treating stages on the same animal. These imaging modalities will greatly enhance the research activities in biomedical research.
Prof. Qiushi Ren
Department of Biomedical Engineering, Peking University, Professor
Page views: 1944